Previously Untreated Advanced Urothelial Carcinoma: Update From ESMO 2023
Drs. Rosenberg and Morgans share their insights into 2 late‑breaking abstracts presented at ESMO 2023 on the first‑line treatment of metastatic urothelial carcinoma: EV‑302 on the combination of enfortumab vedotin and pembrolizumab and CheckMate 901 on the combination of nivolumab and gemcitabine/cisplatin.
PV Roundup - Medical News Podcast
en-usMarch 08, 2024